Stock listing

gettex:I9DN Arbutus Biopharma Corporation Aktie

German listing (gettex) of Arbutus Biopharma Corporation · home listing NASDAQ:ABUS

Follow Arbutus Biopharma Corporation into a list and get an email when it puts out news.

Home listing price · NASDAQ:ABUS

$4.19 USD +0.08 (+1.9%)

Close on Oct 14, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ABUS

Arbutus Biopharma Corporation logo
Ticker
gettex:I9DN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Calls

Replays

  • Arbutus Biopharma (NASDAQ:ABUS) Q3 2024 Earnings Call

    Wed, Nov 06, 2024 · 8:45 AM ET

    Watch Transcript

  • Arbutus Biopharma (NASDAQ:ABUS) Q2 2024 Earnings Call

    Thu, Aug 01, 2024 · 8:45 AM ET

    Watch Transcript

  • Arbutus Biopharma (NASDAQ:ABUS) Q1 2024 Earnings Call

    Thu, May 02, 2024 · 8:45 AM ET

    Watch Transcript

Latest news

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Oct 1, 2026

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Sep 30, 2026

Arbutus Biopharma Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Aug 24, 2026

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Aug 21, 2026

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 12, 2026

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Jul 16, 2026

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Apr 15, 2026

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Mar 23, 2026

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Mar 3, 2026

All Arbutus Biopharma Corporation news

Decks

Arbutus Biopharma Corporation on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 155 in all · newest Oct 1, 2026 · oldest 2019
Calls
14 calls with a replay · 14 with a transcript · latest Nov 6, 2024
Decks
53 decks · latest Dec 11, 2025

Where Arbutus Biopharma Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:ABUS · Home listingNASDAQUnited StatesUSD
LS Exchange:A14XMDLS ExchangeGermanyEUR
Lang & Schwarz:A14XMDLang & SchwarzGermanyEUR
BOATS:ABUSBOATSUnited StatesUSD
gettex:I9DN · This pagegettexGermanyEUR
LSE:0SGCLSEUnited KingdomUSD
Stuttgart:I9DNStuttgartGermanyEUR
Dusseldorf:I9DNDusseldorfGermanyEUR
Frankfurt:I9DNFrankfurtGermanyEUR
Munich:I9DNMunichGermanyEUR
Tradegate:I9DNTradegateGermanyEUR

Log in to ask 6ix AI your own questions about Arbutus Biopharma Corporation.